Telix Pharmaceuticals (NASDAQ:TLX) executives highlighted commercial momentum in prostate cancer imaging and outlined multiple clinical programs in oncology during an H.C. Wainwright discussion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results